Yes, that was the first thing I thought when I clicked the link (sorry I forgot to mention that). So I looked at the name and title of the investigator that was mentioned (Prof. Sara Gilbert) and found this website:
https://www.ovg.ox.ac.uk/news/covid-19-vaccine-development
Here is an excerpt, which led me to believe their work is legit, but I'd like to see the data and methods of the results that led to their claim that was the focus of the article (hence my cautious optimism):
Scientists around the world are working hard to develop a vaccine to prevent COVID-19, but there is a lot to be done. A team in Oxford led by Prof. Sarah Gilbert, Prof. Andrew Pollard, Prof. Teresa Lambe, Dr Sandy Douglas and Prof. Adrian Hill started work designing a vaccine on Saturday 10th January 2020. The current status is that they have identified a vaccine candidate and are working towards the first clinical testing phase.
A chimpanzee adenovirus vaccine vector (ChAdOx1), developed at Oxford’s Jenner Institute, was chosen as the most suitable vaccine technology for a SARS-CoV-2 vaccine as it can generate a strong immune response from one dose and it is not a replicating virus, so it cannot cause an ongoing infection in the vaccinated individual. This also makes it safer to give to children, the elderly and anyone with a pre-existing condition such as diabetes. Chimpanzee adenoviral vectors are a very well-studied vaccine type, having been used safely in thousands of subjects, from 1 week to 90 years of age, in vaccines targeting over 10 different diseases.
Coronaviruses have club-shaped spikes on their outer coats. Immune responses from other coronavirus studies suggest that these are a good target for a vaccine. The Oxford vaccine contains the genetic sequence of this surface spike protein inside the ChAdOx1 construct. After vaccination, the surface spike protein of the coronavirus is produced, which primes the immune system to attack the coronavirus if it later infects the body. Prof. Gilbert and team have previously developed a vaccine for another human coronavirus disease, which is Middle East Respiratory Syndrome (MERS), and this has shown promise in early clinical trials.
At the same time as preparing for and conducting the first clinical trial, production of the vaccine is being scaled up ready for larger trials, and potentially, future deployment.
Researchers at Oxford University are working with great care, and due haste, in developing a new vaccine for coronavirus. Production is underway and we are recruiting for a clinical trial. If proven effective, a safe coronavirus vaccine could provide an exit strategy for the pandemic and save lives. While we understand the interest, we ask that the media do not continue to contact researchers while this critical work is underway so that they can focus on these efforts. We will issue press releases in due course.